Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Attributional Styles Of Aggressive Boys And Their Mothers, Laura Bickett, Richard Milich, Ronald Brown
Attributional Styles Of Aggressive Boys And Their Mothers, Laura Bickett, Richard Milich, Ronald Brown
Ronald Brown
To determine if mothers of aggressive boys have the same propensity as their sons to infer hostile intentions in ambiguous interpersonal situations, 50 mothers of aggressive and nonaggressive boys were each asked to interpret hypothetical situations involving themselves with their child, their partner, and a peer as well as hypothetical situations involving their child in interaction with classmates and teachers. Their sons also were each requested to interpret hypothetical situations involving themselves with their mother, a teacher, and a classmate. The results indicated that mothers of aggressive boys do share the propensity to infer hostility in ambiguous situations and may, …
Atomoxetine Treatment In Children And Adolescents With Attention-Deficit Hyperactivity Disorder: What Are The Long-Term Health-Related Quality-Of-Life Outcomes?, Amy Perwien, Christopher Kratochvil, Douglas Faries, Brigette Vaughan, Thomas Spencer, Ronald Brown
Atomoxetine Treatment In Children And Adolescents With Attention-Deficit Hyperactivity Disorder: What Are The Long-Term Health-Related Quality-Of-Life Outcomes?, Amy Perwien, Christopher Kratochvil, Douglas Faries, Brigette Vaughan, Thomas Spencer, Ronald Brown
Ronald Brown
OBJECTIVE: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD. METHODS: Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health …